Granules India, a Rs. 650 crore plus Hyderabad based pharma major, has posted impressive performance during the year ended March 2012 on account of significant growth in sales of finished dosage, pharmaceutical formulation intermediate and APIs. The consolidated net profit increased sharply by 43.3 per cent to Rs. 29.95 crore from Rs. 20.90 crore in the previous year. Its consolidated net sales went up by 37.6 per cent to Rs. 654 crore from Rs. 475 crore.
With strong growth in profits, earnings per share moved up to Rs. 14.93 from Rs. 10.42 in the last period. The Board of Directors has recommended equity dividend of 20 per cent for the year 2011-12. As against the equity capital of Rs. 20.06 crore, its reserves and surplus stood at Rs. 229.69 crore. Its EBDITA touched to Rs. 79.76 crore from Rs. 57.06 crore, a growth of 39.8 per cent.
Granules is currently tripling finished dosage capacity to 18 billion units and more than doubling formulation intermediate capacity to 18,000 tons. The expansions are scheduled to finish in June. It will start generating revenue from the new capacities starting in the second quarter of FY'13.
Krishna Prasad, managing director, said, “While the past fiscal year was rewarding, we have continued to take the necessary steps to ensure we can accelerate our growth rate and build sustainable revenue. Granules has established a business model that will continue to accelerate in growth while simultaneously increasing profit margins. We believe FY13 will be one of our most exciting years; our top-line growth will further accelerate and our margins will improve due to higher capacity utilisation and a favourable product mix.”
Dr Bhaskar Kriishna, CEO, said, “Granules has spent tremendous energy improving our operations and we believe our facilities are among the most productive ones in the world. In the past year, we completed several operational excellence projects that enabled us to increase API capacities. Our paracetamol API facility produced 1,000 tons in March which is a tremendous accomplishment considering the facility was intended to produce 600 tons/month at its inauguration and only recently produced 800 tons/month. We also made improvements that increased our metformin API capacity by 35 per cent and guaifenesin API capacity by 55 per cent.”